Humanized monoclonal antibody immunoglobulin G4 against PD-1’s approval was granted in 2015 based on a randomized phase III study that compared it with docetaxel in patients with advanced NSCLC [34]. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.